TABLE 3.

Primary and Secondary Outcomes

CharacteristicPlacebo (n = 16)Fluticasone (n = 16)P Value
Duration of treatment, study days*25 ± 9.027 ± 7.5.49
Study days with oxygen supplement*19 ± 10.521 ± 7.9.55
Total days with oxygen supplement, from birth to study end*65 ± 14.267 ± 13.3.65
Supplemental oxygen-free days, from birth to study end*9 ± 11.79 ± 9.3.48
Length of hospital stay, d*132 ± 87115 ± 69.54
Time to extubation, d8 (2–44)8 (4–12).35
Time to delivery from mechanical ventilation and/or CPAP from study entry, d*15 ± 9.314 ± 7.9.77
  • CPAP indicates continuous positive airway pressure.

  • * Mean ± SD.

  • Median ± range, n = 5 in each group.